Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Safety and Tolerability Results Phase 1 trials demonstrated that Retatrutide was generally well-tolerated across the tested dose range
DOSING USED IN PHASE 3 STUDIES In the most recent studies from the TRIUMPH programme (Phase 3) , retatrutide was administered as follows: Route: Subcutaneous Frequency: Once weekly Study duration: Approximately 68 weeks Phase 3 Schedule Recommended Dosage (Clinical Research Escalation Model) Retatrutide is administered once weekly using a gradual dose escalation to improve tolerability
Linge, J
Most nuanced questions about things like medication ingredients and dosing are left up to the clinicians you speak to during your intake appointment
Every client has different needs, schedules, and goals, which means no single plan works for everyone
US$ 23.12
US$ 25.45
US$ 24.75
US$ 27.11
US$ 20.37
US$ 24.74
